AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35238785 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth literacy among OHI seekers
Number of subjects: 76
Study 35238785 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher eHealth literacy
Number of subjects: 76
Study 35238793 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-CR (mobile health cardiac rehabilitation)
Number of subjects: 400
Study 35238793 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 400
Study 35238854 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic ex vivo kidney perfusion (NEVKP)
Number of subjects: 39
Study 35238854 — intervention group
Group type: COMPARATOR
Intervention: Anoxic hypothermic machine perfusion (Control)
Number of subjects: 39
Study 35239084 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sTFR
Number of subjects: 1244
Study 35239084 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum RBP (Vitamin A)
Number of subjects: 1244
Study 35239084 — intervention group
Group type: COMPARATOR
Intervention: Maternal iron status (ferritin and BIS) and anemia (hemoglobin)
Number of subjects: 1244
Study 35239526 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal hemorrhoidal dearterialization
Number of subjects: 80
Study 35239526 — intervention group
Group type: COMPARATOR
Intervention: Vessel-sealing device hemorrhoidectomy
Number of subjects: 80
Study 35239543 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (App) for pain assessment, used by 49% of parents (n = 772) at least once, for a duration of 10 days.
Number of subjects: 1573
Study 35239543 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessments of pain using a numerical rating scale (NRS)-11 for children older than 6 years.
Number of subjects: 1573
Study 35239543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain medication, preoperative anxiety, postoperative nausea and vomiting, and parent satisfaction were analyzed.
Number of subjects: 1573
Study 35239678 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSD users (prolonged use ≥ 4 weeks)
Number of subjects: 246
Study 35239678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function (measured by MMSE)
Number of subjects: 246
Study 35239678 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSD use
Number of subjects: 246
Study 35239678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognistat
Number of subjects: 246
Study 35239678 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock Drawing Test
Number of subjects: 246
Study 35239692 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU diary
Number of subjects: 5
Study 35239732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate, initial dose adjusted to maintain serum phosphorus at 3.5-5.5 mg/dL, mean dose of 3.35±1.49 g/day (range 1.5 to 6.0 g/day)
Number of subjects: 202
Study 35239732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 202
Study 35240856 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) imaging in patients with idiopathic DCM
Number of subjects: 1204
Study 35240856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic-pattern LGE identified in patients with idiopathic DCM
Number of subjects: 1204
Study 35240856 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography results in patients with transmural or subendocardial LGE
Number of subjects: 1204
Study 35241101 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary saturated fatty acids (SFAs)
Number of subjects: 409
Study 35241119 — intervention group
Group type: COMPARATOR
Intervention: Conventional D-dimer threshold
Number of subjects: 368
Study 35241119 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted D-dimer threshold
Number of subjects: 368
Study 35241119 — intervention group
Group type: EXPERIMENTAL
Intervention: Wells-adjusted D-dimer threshold
Number of subjects: 368
Study 35241119 — intervention group
Group type: EXPERIMENTAL
Intervention: YEARS-adjusted D-dimer threshold
Number of subjects: 368
Study 35241141 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of autologous, adipose-derived mesenchymal stem cells (adMSCs) at a dose of 2×10^6 cells
Number of subjects: 15
Study 35241141 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of autologous, adipose-derived mesenchymal stem cells (adMSCs)
Number of subjects: 15
Study 35241151 — intervention group
Group type: EXPERIMENTAL
Intervention: Human umbilical cord MSCs injected twice into the uterus
Number of subjects: 10
Study 35241226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic-dose enoxaparin
Number of subjects: 3600
Study 35241226 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose enoxaparin
Number of subjects: 3600
Study 35241226 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose apixaban
Number of subjects: 3600
Study 35241240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (HT) in females aged ≥60 years (N = 2,153, 47.6%)
Number of subjects: 6873
Study 35241240 — intervention group
Group type: COMPARATOR
Intervention: Females
Number of subjects: 6873
Study 35241276 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-profile RelayPro thoracic endograft
Number of subjects: 110
Study 35241362 — intervention group
Group type: EXPERIMENTAL
Intervention: Residing in a state with restrictive HIV testing policies
Number of subjects: 612
Study 35241475 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclampsia awareness before diagnosis
Number of subjects: 833
Study 35241475 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of symptoms of pre-eclampsia
Number of subjects: 833
Study 35241475 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in decision making at diagnosis
Number of subjects: 833
Study 35241475 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in awareness of symptoms of pre-eclampsia over time
Number of subjects: 833
Study 35241475 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling about later-life health risks associated with pre-eclampsia
Number of subjects: 833
Study 35241644 — intervention group
Group type: EXPERIMENTAL
Intervention: Branaplam, an orally available, brain penetrant small molecule
Number of subjects: 0
Study 35241844 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µg booster injection of mRNA-1273
Number of subjects: 344
Study 35241942 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone (controlled-release 10 mg every 12 hours and immediate-release 5 mg every 4 hours as needed)
Number of subjects: 60
Study 35241942 — intervention group
Group type: COMPARATOR
Intervention: Oral tramadol (controlled-release 100 mg every 8 hours and immediate-release 50 mg every 4 hours as needed)
Number of subjects: 60
Study 35242224 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about behavioural risk factors of cancer
Number of subjects: 200
Study 35242224 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 200
Study 35242224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 200
Study 35242224 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of street food
Number of subjects: 200
Study 35242224 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of packed-fried snacks
Number of subjects: 200
Study 35242593 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines with still images
Number of subjects: 0
Study 35242593 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines with 360° navigable images
Number of subjects: 0
Study 35242593 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 35242627 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 IgG Abs determination using ELISA kit from NovaLisa targeting recombinant antigen N of the nucleocapsid of SARS-CoV-2.
Number of subjects: 1500
Study 35242627 — intervention group
Group type: EXPERIMENTAL
Intervention: Second determination of IgG levels after an average of 4.5 months (IQR 4.0-5.0 months).
Number of subjects: 1500
Study 35242627 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of severity of infection and hospitalization needs.
Number of subjects: 1500
Study 35242627 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of symptoms at diagnosis.
Number of subjects: 1500
Study 35242683 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pyrotinib 400 mg once daily, trastuzumab 4 mg/kg loading dose followed by 2 mg/kg once a week, and albumin-bound paclitaxel 125 mg/m2.
Number of subjects: 21
Study 35242683 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pyrotinib plus trastuzumab and albumin-bound paclitaxel
Number of subjects: 21
Study 35242798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient formulation containing DHA, ARA, iron, vitamin B12, folic acid, and sphingomyelin from whey protein concentrate
Number of subjects: 0
Study 35242798 — intervention group
Group type: COMPARATOR
Intervention: Control formulation
Number of subjects: 0
Study 35243302 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sevelamer (800 mg thrice daily, titratable up to 1,200 mg thrice daily)
Number of subjects: 60
Study 35243302 — intervention group
Group type: COMPARATOR
Intervention: Low-dose sevelamer (400 mg thrice daily) with calcium carbonate
Number of subjects: 60
Study 35243302 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sevelamer
Number of subjects: 60
Study 35243302 — intervention group
Group type: COMPARATOR
Intervention: Low-dose sevelamer
Number of subjects: 60
Study 35243320 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster CD-JEV dose
Number of subjects: 560
Study 35243320 — intervention group
Group type: COMPARATOR
Intervention: Primary CD-JEV vaccination
Number of subjects: 560
Study 35243418 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vaccination
Number of subjects: 0
Study 35243473 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineered human acellular vessels (HAVs) implanted for dialysis access
Number of subjects: 40
Study 35243592 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 928
Study 35243870 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 21237
Study 35243870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists
Number of subjects: 21237
Study 35243870 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 21237
Study 35243870 — intervention group
Group type: EXPERIMENTAL
Intervention: DOACs in Europe
Number of subjects: 21237
Study 35243870 — intervention group
Group type: COMPARATOR
Intervention: DOACs in Asia
Number of subjects: 21237
Study 35243870 — intervention group
Group type: COMPARATOR
Intervention: DOACs in Latin America
Number of subjects: 21237
Study 35243921 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Score (HYPS)
Number of subjects: 783
Study 35244208 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose anticoagulants
Number of subjects: 16185
Study 35244208 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulants
Number of subjects: 16185
Study 35244520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for up to 2 years
Number of subjects: 28
Study 35244520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 28
Study 35244681 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA-T infusions at doses of 0.5 to 4 × 10^7/m2
Number of subjects: 23
Study 35244681 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA-T infusions
Number of subjects: 23
Study 35244756 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab (R 375 mg/m2)
Number of subjects: 0
Study 35244820 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ECG TTM (30 s recordings)
Number of subjects: 50
Study 35244820 — intervention group
Group type: COMPARATOR
Intervention: Holter ECG (6-day recordings)
Number of subjects: 50
Study 35244820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (TTM and Holter ECG)
Number of subjects: 50
Study 35244820 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ECG TTM
Number of subjects: 50
Study 35244820 — intervention group
Group type: COMPARATOR
Intervention: Holter ECG
Number of subjects: 50
Study 35245100 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garment wear adherence
Number of subjects: 0
Study 35245205 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GHT)
Number of subjects: 69
Study 35245341 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid formulation of Vitamin B12 delivered during breastfeeding
Number of subjects: 26
Study 35245341 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid formulation of Vitamin B12
Number of subjects: 26
Study 35245407 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory phenotype
Number of subjects: 2328
Study 35245407 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscus/cartilage phenotype
Number of subjects: 2328
Study 35245407 — intervention group
Group type: EXPERIMENTAL
Intervention: Subchondral bone phenotype
Number of subjects: 2328
Study 35245407 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophic phenotype (females)
Number of subjects: 2328
Study 35246024 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum positive end-expiratory pressure (PEEP) level on Day 1
Number of subjects: 116
Study 35246024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitability
Number of subjects: 116
Study 35246024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung overdistension
Number of subjects: 116
Study 35246024 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas exchange improvements in survivors after Day 7
Number of subjects: 116
Study 35246109 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) adherence during the COVID-19 pandemic
Number of subjects: 8477
Study 35246222 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA group
Number of subjects: 21
Study 35246222 — intervention group
Group type: EXPERIMENTAL
Intervention: IMUs
Number of subjects: 21
Study 35246398 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisense oligonucleotides targeting FUS
Number of subjects: 0
Study 35246452 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 220
Study 35246452 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 220
Study 35246457 — intervention group
Group type: EXPERIMENTAL
Intervention: C1) low tissue turnover
Number of subjects: 0
Study 35246457 — intervention group
Group type: EXPERIMENTAL
Intervention: C2) structural damage
Number of subjects: 0
Study 35246457 — intervention group
Group type: EXPERIMENTAL
Intervention: C3) systemic inflammation
Number of subjects: 0
Study 35246470 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 111
Study 35246470 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg
Number of subjects: 111
Study 35246595 — intervention group
Group type: EXPERIMENTAL
Intervention: His bundle pacing (HBP) using the EnSite AutoMap Module for automated assessment of QRS morphology.
Number of subjects: 43
Study 35246595 — intervention group
Group type: EXPERIMENTAL
Intervention: His-lead stimulation with an intrinsic morphology match score (IMS) ≥ 89%.
Number of subjects: 43
Study 35246595 — intervention group
Group type: EXPERIMENTAL
Intervention: His-lead stimulation with an IMS between 78 and < 89%.
Number of subjects: 43
Study 35246776 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-7 ex vivo administration
Number of subjects: 0
Study 35246776 — intervention group
Group type: COMPARATOR
Intervention: Control (no rhIL-7)
Number of subjects: 0
Study 35247067 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of glycaemic control
Number of subjects: 8
Study 35247086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib 300 mg orally once daily plus pembrolizumab
Number of subjects: 16
Study 35247086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib 300 mg orally once daily plus nivolumab
Number of subjects: 16
Study 35247086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib 400 mg orally once daily
Number of subjects: 16
Study 35247086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib 300 mg orally once daily
Number of subjects: 16
Study 35247086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib (300 or 400 mg)
Number of subjects: 16
Study 35247191 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (tranexamic acid)
Number of subjects: 17
Study 35247191 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of in vivo plasmin activation
Number of subjects: 17
Study 35247274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (200 mg single dose) in subjects with mild hepatic impairment
Number of subjects: 40
Study 35247274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (200 mg single dose) in subjects with moderate hepatic impairment
Number of subjects: 40
Study 35247274 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 40
Study 35247824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training program
Number of subjects: 11
Study 35247913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg as the recommended phase II dose, taken orally for 21 consecutive days of 28-day cycles)
Number of subjects: 38
Study 35247913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 38
Study 35247923 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 108
Study 35247983 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 70+
Number of subjects: 4806
Study 35247983 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 4806
Study 35247983 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 4806
Study 35247983 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 4806
Study 35247983 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pulmonary obstructive disease (COPD)
Number of subjects: 4806
Study 35247983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing comorbidities
Number of subjects: 4806
Study 35248013 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral neck irradiation
Number of subjects: 29
Study 35248212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir (400 mg sofosbuvir, 100 mg velpatasvir, 100 mg voxilaprevir) once daily for 12 weeks
Number of subjects: 40
Study 35248213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and Velpatasvir (100 mg) once-daily for 12 weeks
Number of subjects: 61
Study 35248213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir
Number of subjects: 61
Study 35248647 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 10 mg/mL
Number of subjects: 0
Study 35248647 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 40 mg/mL
Number of subjects: 0
Study 35248647 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 100 mg/mL
Number of subjects: 0
Study 35248866 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-411 (4 mg, 8 mg, 12 mg, and 16 mg once daily until maximum tolerated dose)
Number of subjects: 77
Study 35248866 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-411 (8 mg once daily, recommended phase II dose)
Number of subjects: 77
Study 35248866 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-411 (all doses)
Number of subjects: 77
Study 35249039 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) obesity definition
Number of subjects: 970
Study 35249039 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 970
Study 35249039 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) in low BMI
Number of subjects: 970
Study 35249039 — intervention group
Group type: COMPARATOR
Intervention: Body mass index (BMI)
Number of subjects: 970
Study 35249113 — intervention group
Group type: EXPERIMENTAL
Intervention: β-lactams
Number of subjects: 66
Study 35249113 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline relative abundances of 2 Bacteroides species
Number of subjects: 66
Study 35249113 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline abundance of Lachnospiraceae and amino acid biosynthesis pathways
Number of subjects: 66
Study 35249113 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in the AAD group
Number of subjects: 66
Study 35249113 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota compositional profiles
Number of subjects: 66
Study 35249439 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 170
Study 35249439 — intervention group
Group type: COMPARATOR
Intervention: bDMARDs
Number of subjects: 170
Study 35249485 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV9-coGLB1 gene therapy, injected via caudal vein at 4 weeks of age, sustained expression for up to 32 weeks.
Number of subjects: 0
Study 35249540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for ADHD symptoms (specific medication not detailed)
Number of subjects: 323
Study 35249706 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered via target-controlled infusion
Number of subjects: 36
Study 35249706 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanistic pharmacodynamic model
Number of subjects: 36
Study 35249706 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical models for MAP, HR, and PP
Number of subjects: 36
Study 35249841 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-IMR > 40 U
Number of subjects: 285
Study 35249841 — intervention group
Group type: COMPARATOR
Intervention: Angio-IMR ≤ 40 U
Number of subjects: 285
Study 35249841 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-IMR
Number of subjects: 285
Study 35249968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab and dexamethasone
Number of subjects: 111
Study 35249968 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (control)
Number of subjects: 111
Study 35250203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic endoderm cells implanted in nonimmunoprotective macroencapsulation devices
Number of subjects: 0